Meeder Asset Management’s Charles River Laboratories CRL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $4.99K | Sell |
22
-1,895
| -99% | -$337K | ﹤0.01% | 840 |
|
|
2026
Q1 | $331K | Buy |
+1,917
| New | +$355K | 0.02% | 261 |
|
|
2025
Q2 | – | Sell |
-19
| Closed | -$2.86K | – | 886 |
|
|
2025
Q1 | $2.86K | Sell |
19
-8
| -30% | -$1.34K | ﹤0.01% | 840 |
|
|
2024
Q4 | $4.98K | Buy |
+27
| New | +$5.2K | ﹤0.01% | 833 |
|
|
2024
Q3 | – | Sell |
-31
| Closed | -$6.4K | – | 860 |
|
|
2024
Q2 | $6.4K | Sell |
31
-304
| -91% | -$68.9K | ﹤0.01% | 737 |
|
|
2024
Q1 | $90.8K | Sell |
335
-546
| -62% | -$130K | 0.01% | 336 |
|
|
2023
Q4 | $208K | Hold |
881
| – | – | 0.02% | 304 |
|
|
2023
Q3 | $173K | Hold |
881
| – | – | 0.01% | 318 |
|
|
2023
Q2 | $185K | Hold |
881
| – | – | 0.01% | 328 |
|
|
2023
Q1 | $178K | Buy |
+881
| New | +$200K | 0.01% | 348 |
|
|
2022
Q4 | – | Sell |
-157
| Closed | -$31K | – | 1046 |
|
|
2022
Q3 | $31K | Sell |
157
-129
| -45% | -$27.8K | ﹤0.01% | 971 |
|
|
2022
Q2 | $61K | Sell |
286
-137
| -32% | -$33.5K | ﹤0.01% | 825 |
|
|
2022
Q1 | $120K | Sell |
423
-1,127
| -73% | -$348K | 0.01% | 765 |
|
|
2021
Q4 | $585K | Sell |
1,550
-161
| -9% | -$62.6K | 0.06% | 197 |
|
|
2021
Q3 | $707K | Sell |
1,711
-758
| -31% | -$315K | 0.04% | 332 |
|
|
2021
Q2 | $913K | Buy |
2,469
+22
| +0.9% | +$7.35K | 0.04% | 293 |
|
|
2021
Q1 | $710K | Buy |
2,447
+2,401
| +5,220% | +$667K | 0.04% | 347 |
|
|
2020
Q4 | $11K | Sell |
46
-3,005
| -98% | -$716K | ﹤0.01% | 956 |
|
|
2020
Q3 | $692K | Buy |
3,051
+2,248
| +280% | +$467K | 0.04% | 293 |
|
|
2020
Q2 | $140K | Sell |
803
-22
| -3% | -$3.51K | 0.01% | 684 |
|
|
2020
Q1 | $105K | Buy |
825
+401
| +95% | +$60.1K | 0.01% | 699 |
|
|
2019
Q4 | $65K | Buy |
424
+5
| +1% | +$692 | ﹤0.01% | 941 |
|
|
2019
Q3 | $56K | Buy |
419
+11
| +3% | +$1.48K | ﹤0.01% | 972 |
|
|
2019
Q2 | $58K | Buy |
408
+8
| +2% | +$1.08K | ﹤0.01% | 907 |
|
|
2019
Q1 | $58K | Sell |
400
-990
| -71% | -$130K | ﹤0.01% | 835 |
|
|
2018
Q4 | $157K | Buy |
1,390
+524
| +61% | +$65.6K | 0.01% | 554 |
|
|
2018
Q3 | $117K | Buy |
866
+184
| +27% | +$22.7K | 0.01% | 611 |
|
|
2018
Q2 | $76.6K | Sell |
682
-53
| -7% | -$5.73K | 0.01% | 674 |
|
|
2018
Q1 | $78K | Sell |
735
-876
| -54% | -$94.4K | 0.01% | 592 |
|
|
2017
Q4 | $176K | Sell |
1,611
-4,139
| -72% | -$450K | 0.02% | 481 |
|
|
2017
Q3 | $622K | Buy |
5,750
+4,767
| +485% | +$490K | 0.07% | 328 |
|
|
2017
Q2 | $99K | Sell |
983
-3,134
| -76% | -$288K | 0.01% | 559 |
|
|
2017
Q1 | $370K | Sell |
4,117
-2,932
| -42% | -$249K | 0.03% | 427 |
|
|
2016
Q4 | $537K | Buy |
7,049
+642
| +10% | +$48.8K | 0.05% | 352 |
|
|
2016
Q3 | $534K | Buy |
6,407
+3,358
| +110% | +$281K | 0.05% | 414 |
|
|
2016
Q2 | $250K | Buy |
+3,049
| New | +$251K | 0.02% | 544 |
|
|
2014
Q2 | – | Sell |
-35,855
| Closed | -$2.16M | – | 341 |
|
|
2014
Q1 | $2.16M | Buy |
+35,855
| New | +$2.09M | 0.36% | 80 |
|
|
2013
Q3 | – | Sell |
-5,350
| Closed | -$220K | – | 358 |
|
|
2013
Q2 | $220K | Buy |
+5,350
| New | +$229K | 0.04% | 266 |
|
Other funds holding CRL
AI
Meeder Asset Management's CRL Position: Q2 2026 in Review
Meeder Asset Management reduced its Charles River Laboratories (CRL) stake by 99% in Q2 2026, selling an estimated $337K and leaving 22 shares worth $4.99K. The position accounts for ﹤0.01% of the portfolio, ranked #840.
Meeder Asset Management first reported a position in CRL in Q2 2013 and has held it in 38 quarters since. The position peaked at $2.16M in Q1 2014. 570 funds tracked by Wall St. Rank hold CRL as of Q2 2026.
- Meeder Asset Management held 22 shares of Charles River Laboratories worth $4.99K as of Q2 2026.
- Meeder Asset Management sold 1,895 Charles River Laboratories shares in Q2 2026, an estimated $337K.
- Charles River Laboratories made up ﹤0.01% of Meeder Asset Management's portfolio in Q2 2026, its #840 holding.
- Meeder Asset Management first reported a position in Charles River Laboratories in Q2 2013 and has held it in 38 quarters since.
- Meeder Asset Management's Charles River Laboratories position peaked at $2.16M in Q1 2014.
- 570 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2026.
Based on Meeder Asset Management's 13F filing for Q2 2026, filed 7 Aug 2026.